CHAMPIONS ONCOLOGY, INC. (CSBR) Spending and interest coverage
- R&D / revenue · 12 months: Value 15.41%; Formula and calculation Research and development expense / revenue. Period ending 2026-07-31..
- Stock-based compensation / revenue · 12 months: Value 2.96%; Formula and calculation Share-based compensation / revenue. Period ending 2026-07-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 15.41% | Research and development expense / revenue. Period ending 2026-07-31. $9.35M ÷ $60.66M × 100 ≈ 15.41% |
| Stock-based compensation / revenue · 12 months | 2.96% | Share-based compensation / revenue. Period ending 2026-07-31. $1.79M ÷ $60.66M × 100 ≈ 2.96% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 9.35M USD | Research and Development Expense |
| Revenue | 60.66M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.79M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -1.02M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | $9.35M | $60.66M | $1.79M | $-1.02M | (m) | 15.41% | 2.96% | (m) | (m) |
| 2026-04-30 | $9.08M | $59.42M | $1.24M | $-1.14M | (m) | 15.29% | 2.08% | (m) | (m) |
| 2026-01-31 | $8.93M | $57.95M | $1.01M | $-2.63M | (m) | 15.41% | 1.74% | (m) | (m) |
| 2025-10-31 | $8.38M | $58.42M | $844.00K | $2.15M | (m) | 14.34% | 1.44% | (m) | (m) |
| 2025-07-31 | $7.45M | $56.88M | $604.00K | $2.70M | (m) | 13.10% | 1.06% | (m) | (m) |
| 2025-04-30 | $6.83M | $56.94M | $654.00K | $4.55M | (m) | 11.99% | 1.15% | (m) | (m) |
| 2025-01-31 | $6.91M | $58.59M | $786.00K | $6.29M | (m) | 11.80% | 1.34% | (m) | (m) |
| 2024-10-31 | $7.38M | $53.57M | $909.00K | $-788.00K | (m) | 13.77% | 1.70% | (m) | (m) |
| 2024-07-31 | $8.21M | $51.66M | $953.00K | $-3.48M | (m) | 15.88% | 1.84% | (m) | (m) |
| 2024-04-30 | $9.54M | $50.16M | $1.12M | $-7.36M | (m) | 19.03% | 2.23% | (m) | (m) |
| 2024-01-31 | $10.35M | $49.22M | $1.06M | $-9.61M | (m) | 21.02% | 2.16% | (m) | (m) |
| 2023-10-31 | $11.36M | $49.98M | $1.01M | $-9.49M | (m) | 22.73% | 2.03% | (m) | (m) |
| 2023-07-31 | $11.45M | $52.69M | $1.08M | $-7.52M | (m) | 21.73% | 2.05% | (m) | (m) |
| 2023-04-30 | $11.54M | $53.87M | $864.00K | $-5.26M | (m) | 21.43% | 1.60% | (m) | (m) |
| 2023-01-31 | $11.28M | $53.68M | $844.00K | $-3.05M | (m) | 21.02% | 1.57% | (m) | (m) |
| 2022-10-31 | $10.26M | $54.10M | $823.00K | $242.00K | (m) | 18.97% | 1.52% | (m) | (m) |
| 2022-07-31 | $9.96M | $51.60M | $838.00K | $498.00K | (m) | 19.30% | 1.62% | (m) | (m) |
| 2022-04-30 | $9.37M | $49.11M | $912.00K | $607.00K | (m) | 19.09% | 1.86% | (m) | (m) |
| 2022-01-31 | $8.85M | $46.80M | $885.00K | $270.00K | (m) | 18.92% | 1.89% | (m) | (m) |
| 2021-10-31 | $8.55M | $44.41M | $807.00K | $423.00K | (m) | 19.25% | 1.82% | (m) | (m) |
| 2021-07-31 | $7.90M | $42.75M | $758.00K | $167.00K | (m) | 18.49% | 1.77% | (m) | (m) |
| 2021-04-30 | $7.20M | $41.04M | $598.00K | $366.00K | (m) | 17.53% | 1.46% | (m) | (m) |
| 2021-01-31 | $6.94M | $39.22M | $600.00K | $-1.12M | (m) | 17.70% | 1.53% | (m) | (m) |
| 2020-10-31 | $6.46M | $37.42M | $597.00K | $-1.45M | (m) | 17.25% | 1.60% | (m) | (m) |
| 2020-07-31 | $6.15M | $34.93M | $589.00K | $-1.17M | (m) | 17.60% | 1.69% | (m) | (m) |
| 2020-04-30 | $5.85M | $32.12M | $600.00K | $-1.80M | (m) | 18.22% | 1.87% | (m) | (m) |
| 2020-01-31 | $5.28M | $31.09M | $575.00K | $-7.00K | (m) | 16.99% | 1.85% | (m) | (m) |
| 2019-10-31 | $5.16M | (m) | $681.00K | $-810.00K | (m) | (m) | (m) | (m) | (m) |
| 2019-07-31 | $5.01M | (m) | $692.00K | $-825.00K | (m) | (m) | (m) | (m) | (m) |
| 2019-04-30 | $4.80M | $27.07M | $636.00K | $270.00K | (m) | 17.73% | 2.35% | (m) | (m) |
| 2019-01-31 | $4.64M | (m) | $654.00K | $-213.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-10-31 | $4.45M | (m) | $456.00K | $92.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-07-31 | $4.37M | (m) | $515.00K | $-254.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-04-30 | $4.40M | (m) | $1.00M | $-1.35M | (m) | (m) | (m) | (m) | (m) |
| 2018-01-31 | $4.38M | (m) | $1.61M | $-3.14M | (m) | (m) | (m) | (m) | (m) |
| 2017-10-31 | $4.31M | (m) | $1.71M | $-4.48M | (m) | (m) | (m) | (m) | (m) |
| 2017-07-31 | $4.20M | (m) | $2.10M | $-4.91M | (m) | (m) | (m) | (m) | (m) |
| 2017-04-30 | $4.29M | (m) | $2.66M | $-6.81M | (m) | (m) | (m) | (m) | (m) |
| 2017-01-31 | $4.39M | (m) | $2.41M | $-6.97M | (m) | (m) | (m) | (m) | (m) |
| 2016-10-31 | $4.39M | (m) | $2.74M | $-7.94M | (m) | (m) | (m) | (m) | (m) |
| 2016-07-31 | $4.30M | (m) | $2.95M | $-9.94M | (m) | (m) | (m) | (m) | (m) |
| 2016-04-30 | $4.19M | (m) | $2.60M | $-10.32M | (m) | (m) | (m) | (m) | (m) |
| 2016-01-31 | $4.11M | (m) | $2.97M | $-10.17M | (m) | (m) | (m) | (m) | (m) |
| 2015-10-31 | $4.20M | (m) | $3.06M | $-11.24M | (m) | (m) | (m) | (m) | (m) |
| 2015-07-31 | $4.52M | (m) | $3.13M | $-12.41M | (m) | (m) | (m) | (m) | (m) |
| 2015-04-30 | $4.84M | (m) | $3.16M | $-13.24M | (m) | (m) | (m) | (m) | (m) |
| 2015-01-31 | $4.41M | (m) | $3.12M | $-13.21M | (m) | (m) | (m) | (m) | (m) |
| 2014-10-31 | $3.85M | (m) | $3.41M | $-11.18M | (m) | (m) | (m) | (m) | (m) |
| 2014-07-31 | $3.29M | (m) | $3.06M | $-9.22M | (m) | (m) | (m) | (m) | (m) |
| 2014-04-30 | $2.27M | (m) | $2.81M | $-6.26M | (m) | (m) | (m) | (m) | (m) |
| 2014-01-31 | $2.12M | (m) | $2.41M | $-5.87M | (m) | (m) | (m) | (m) | (m) |
| 2013-10-31 | $2.18M | (m) | $2.04M | $-5.18M | (m) | (m) | (m) | (m) | (m) |
| 2013-07-31 | $1.94M | (m) | $2.19M | $-5.39M | (m) | (m) | (m) | (m) | (m) |
| 2013-04-30 | $1.92M | (m) | $2.38M | $-6.22M | (m) | (m) | (m) | (m) | (m) |
| 2013-01-31 | $1.79M | (m) | $2.65M | $-6.84M | (m) | (m) | (m) | (m) | (m) |
| 2012-10-31 | $2.14M | (m) | $2.82M | $-7.90M | (m) | (m) | (m) | (m) | (m) |
| 2012-07-31 | $2.78M | (m) | $3.05M | $-8.45M | (m) | (m) | (m) | (m) | (m) |
| 2012-04-30 | $2.94M | (m) | $3.32M | $-9.06M | (m) | (m) | (m) | (m) | (m) |
| 2012-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-30 | $2.91M | (m) | $3.13M | $-5.24M | (m) | (m) | (m) | (m) | (m) |
| 2011-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |